100 related articles for article (PubMed ID: 28601379)
1. A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer.
PEBC’s Ovarian Oncology Guidelines Group
Gynecol Oncol; 2017 Aug; 146(2):392-398. PubMed ID: 28601379
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.
Frey MK; Ellis AE; Koontz LM; Shyne S; Klingenberg B; Fields JC; Chern JY; Blank SV
Gynecol Oncol; 2017 Aug; 146(2):386-391. PubMed ID: 28602549
[TBL] [Abstract][Full Text] [Related]
3. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV).
Rohr I; Alavi S; Richter R; Keller M; Chekerov R; Oskay-Özcelik G; Heinrich M; Taskiran C; Joly F; Berger R; du Bois A; Gornjec A; Vergote I; Achimas-Cadariu P; Lorusso D; Maenpaa J; Sehouli J
Int J Gynecol Cancer; 2020 Apr; 30(4):509-514. PubMed ID: 32139438
[TBL] [Abstract][Full Text] [Related]
4. Patient preferences in advanced or recurrent ovarian cancer.
Havrilesky LJ; Alvarez Secord A; Ehrisman JA; Berchuck A; Valea FA; Lee PS; Gaillard SL; Samsa GP; Cella D; Weinfurt KP; Abernethy AP; Reed SD
Cancer; 2014 Dec; 120(23):3651-9. PubMed ID: 25091693
[TBL] [Abstract][Full Text] [Related]
5. Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.
Sjoquist KM; Friedlander ML; O'Connell RL; Voysey M; King MT; Stockler MR; Oza AM; Gillies K; Martyn JK; Butow PN
Oncologist; 2013; 18(11):1221-8. PubMed ID: 24107972
[TBL] [Abstract][Full Text] [Related]
6. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
Havrilesky LJ; Lim S; Ehrisman JA; Lorenzo A; Alvarez Secord A; Yang JC; Johnson FR; Gonzalez JM; Reed SD
Gynecol Oncol; 2020 Mar; 156(3):561-567. PubMed ID: 31982178
[TBL] [Abstract][Full Text] [Related]
7. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato FT; Joly F; O'Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M;
Oncologist; 2017 Sep; 22(9):1117-1124. PubMed ID: 28596446
[TBL] [Abstract][Full Text] [Related]
8. Differences in Preferences for Drug Therapy Between Patients with Metastatic Versus Early-Stage Breast Cancer: A Systematic Literature Review.
Brandstetter LS; Jírů-Hillmann S; Störk S; Heuschmann PU; Wöckel A; Reese JP
Patient; 2024 Jul; 17(4):349-362. PubMed ID: 38451419
[TBL] [Abstract][Full Text] [Related]
9. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
Patnaik A; Doyle C; Oza AM
Anticancer Drugs; 1998 Nov; 9(10):869-78. PubMed ID: 9890698
[TBL] [Abstract][Full Text] [Related]
10. [Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].
Lorcet M; Lortholary A; Kurtz JE; Berton-Rigaud D; Fabbro M; De La Motte Rouge T; Kaminsky-Forrett MC; Floquet A; Freyer G; Combe P; Dohollou N; Kalbacher E; Despax R; Largillier R; Hardy Bessard AC; Gane N; Sehouli J; Oskay-Oezcelik G; Licaj I; Ray-Coquard I; Joly Lobbedez F
Bull Cancer; 2018 May; 105(5):465-474. PubMed ID: 29544693
[TBL] [Abstract][Full Text] [Related]
11. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
12. Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients.
Beesley VL; Clavarino AM; Webb PM; Wyld DK; Francesconi AB; Horwood KR; Doecke JD; Loos CA; Green AC
Support Care Cancer; 2010 Aug; 18(8):943-9. PubMed ID: 19777270
[TBL] [Abstract][Full Text] [Related]
13. Aggressive management of recurrent ovarian cancer--the challenge of individualizing cancer therapy illustrated by a case report.
Kieback DG; Einzmann T; Labinsky E; Fischer DC; Niebergall H; Hasenburg A
Onkologie; 2004 Aug; 27(4):393-7. PubMed ID: 15347897
[TBL] [Abstract][Full Text] [Related]
14. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Emons G; Kurzeder C; Schmalfeldt B; Neuser P; de Gregorio N; Pfisterer J; Park-Simon TW; Mahner S; Schröder W; Lück HJ; Heubner ML; Hanker L; Thiel F; Hilpert F
Gynecol Oncol; 2016 Mar; 140(3):450-6. PubMed ID: 26731724
[TBL] [Abstract][Full Text] [Related]
15. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy in patients with recurrent or refractory epithelial ovarian cancer.
Satthapong D; Tangjitgamol S; Manusirivithaya S; Pataradool K
J Med Assoc Thai; 2007 Mar; 90(3):411-9. PubMed ID: 17427513
[TBL] [Abstract][Full Text] [Related]
17. Rising cancer antigen 125 level and the type and timing of treatment for recurrent ovarian cancer: a clinical dilemma, but what would women do?
Harrison JD; Juraskova I; Anderson C; Nattress K; Beale P; Lopez AL; Carter J
Int J Gynecol Cancer; 2009 Aug; 19(6):1037-46. PubMed ID: 19820365
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Comparison of Younger and Older Patients' Preferences for Adjuvant Chemotherapy and Hormonal Therapy in Early Breast Cancer.
Hamelinck VC; Bastiaannet E; Pieterse AH; de Glas NA; Portielje JE; Merkus JW; den Hoed ID; van de Velde CJ; Liefers GJ; Stiggelbout AM
Clin Breast Cancer; 2016 Oct; 16(5):379-388. PubMed ID: 27212474
[TBL] [Abstract][Full Text] [Related]
19. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer.
Sun CC; Bodurka DC; Weaver CB; Rasu R; Wolf JK; Bevers MW; Smith JA; Wharton JT; Rubenstein EB
Support Care Cancer; 2005 Apr; 13(4):219-27. PubMed ID: 15538640
[TBL] [Abstract][Full Text] [Related]
20. Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer.
Pyeon SY; Han GH; Ki KD; Lee KB; Lee JM
PLoS One; 2020; 15(7):e0236244. PubMed ID: 32701994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
